Is the Mayo model for predicting survival useful after the introduction of ursodeoxycholic acid treatment for primary biliary cirrhosis?
Open accessAbstract
Treatment of patients with primary biliary cirrhosis (PBC) using ursodeoxycholic acid (UDCA) leads to a reduction in serum bilirubin. The first objective of this study was to assess the performance of certain prognostic indicators for PBC after the introduction of treatment with UDCA. Serum bilirubin is an important prognostic indicator for PBC and an important component of the Mayo model for grading patients into risk categories. In an analysis of patients enrolled in the Canadian multicenter trial, the Mayo score was calculated before and after treatment with UDCA. After treatment, the Mayo score continued to divide patients with PBC into groups with varying risk. In addition, the serum bilirubin alone was shown to do the same even after the introduction of treatment with UDCA. A second objective was to establish whether UDCA had an effect on long-term (2- to 6-year) survival in patients with PBC.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The Mayo risk score and MELD are effective in defining risk groups under UDCA treatment.
“The Mayo risk score and the model for end-stage liver disease (MELD) are also effective in defining risk groups under UDCA treatment [73,74].”
From EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. (2017) · cites this paper as [73]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Prognosis in primary biliary cirrhosis: Model for decision making
Dickson, R. E., Grambsch, P. M., Fleming, T. R., Fisher, L. D., & Langworthy, A. (1989) · Hepatology · doi:10.1002/hep.1840100102 · Cited by 816 · see citing works
Roll, J., Boyer, J. L., Barry, D., & Klatskin, G. (1983) · New England Journal of Medicine · doi:10.1056/nejm198301063080101 · Cited by 417 · see citing works
Flagged first, then by citations
Research works printed but not linked: 11
- Shapiro JM, Smith H, Schaffner F. Serum bilirubin: a prognostic factor in primary bilirubin cirrhosis. Gut 1979;20:137-140. Total serum bilirubin was used to divide the patients 2. Neuberger J, Gunson B, Buckels J, Elias E, McMaster P. Refer- into three groups according to risk. 1 After the introduc- ral of patients with primary bilirubin cirrhosis for liver trans- tion of treatment with UDCA, the survival curves re- plantation. Gut 1990;31:1069-1072.
- hepa WBS: Hepatology 15273350, 1996, 5, · DOI
- Bonsel GJ, Klompmaker IJ, Van 'T Veer F, Habbema JDF, Slooff Pagliaro L, Manenti F, and the Italian Multicenter Group for the Study of UDCA in PBC. Ursodeoxycholic acid for symptomatic MJH. Use of prognostic models for assessment of value of liver primary biliary cirrhosis: preliminary analysis of a double-blind transplantation in primary biliary cirrhosis. Lancet 1990;335: multicenter trial. J Hepatol 1993;17:332-338. 493-497.
- Grambsch PM, Dickson RE, Kaplan M, LeSage G, Fleming TR, 15. Poupon RE, Poupon R, Balkau B, and the UDCA-PBC Study Langworthy AL. Extramural cross-validation of the Mayo pri- Group. Ursodiol for the long-term treatment of primary biliary mary biliary cirrhosis survival model establishes its generaliz- cirrhosis. N Engl J Med 1994;330:1342-1347. ability. HEPATOLOGY 1989;10:846-850.
- MF, Garcia-Tsao G, Boyer JL, et al. A randomized, double-blind, 9. Murtaugh PA, Dickson ER, Van Dam GM, Malinchoc M, placebo-controlled trial of ursodeoxycholic acid (UDCA) in pri- Grambsch PM, Langworthy AL, Gips CH. Primary biliary cirrho- mary biliary cirrhosis. HEPATOLOGY 1993;18:457-481. sis: prediction of short-term survival based on repeated patient 18. Turner IB, Myszor M, Mitchison HC, Bennett MK, Burt AD, visits. HEPATOLOGY 1994;20:126-134.
- Leuschner U, Fischer H, Kurtz W, Gu ¨ldu ¨tuna S, Hu ¨bner K, Hell- ness of ursodeoxycholic acid in primary biliary cirrhosis. J Gas- stern A, Gatzen M, et al. Ursodeoxycholic acid in primary biliary troenterol Hepatol 1994;9:162-168. cirrhosis: results of a controlled double-blind trial. Gastroenter-19.
- Heathcote EJ, Lindor KD, Poupon R, Cauch-Dudek K, Dickson ology 1989;97:1268-1274.
- Oka H, Toda G, Ikeda Y, Hashimoto N, Hasumora Y, Kamimura, can and Canadian randomized controlled trials of ursodeoxy- Ohta Y, et al. A multi-center double-blind controlled trial of urso- cholic acid therapy in primary biliary cirrhosis [Abstract]. Gas- deoxycholic acid for primary biliary cirrhosis. Gastroenterol Jpn troenterology 1995;108:1082. 1990;25:774-780.
- Kaplan EL, Meier P. Non-parametric estimation from incom- 12. Poupon RE, Balkau B, Eschwege E, Poupon R, and the UDCA- plete observations. J Am Stat Assoc 1958;53:457-481.
- PBC Study Group et al. A multicentre controlled trial of ursodiol 21. Poupon RE, Balkau B, Guechot J, Heintzman F. Predictive fac- for the treatment of primary biliary cirrhosis. N Engl J Med tors in ursodeoxycholic acid-treated patients with primary bili- 1991;324:1548-1554. ary cirrhosis: role of serum markers of connective tissue. HEPA- TOLOGY 1994;19:635-640.
- hepa WBS: Hepatology 15273350, 1996, 5, · DOI
Cited by
Sorted by citations
Hirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.022 · Cited by 1,480 · see citing works
Prince, M., Chetwynd, A., Newman, W., Metcalf, J. V., & James, O. F. W. (2002) · Gastroenterology · doi:10.1053/gast.2002.36027 · Cited by 348 · see citing works
Hirschfield, G. M., Dyson, J. K., Alexander, G. J. M., Chapman, M. H., Collier, J., Hübscher, S., Patanwala, I., Pereira, S. P., Thain, C., Thorburn, D., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-315259 · Cited by 347 · see citing works
Goulis, J., Leandro, G., & Burroughs, A. K. (1999) · The Lancet · doi:10.1016/s0140-6736(98)11293-x · Cited by 315 · see citing works
Harms, M. H., van Buuren, H. R., Corpechot, C., Thorburn, D., Janssen, H. L. A., Lindor, K. D., Hirschfield, G. M., Parés, A., Floreani, A., Mayo, M. J., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.04.001 · Cited by 289 · see citing works
Long‐term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis
Angulo, P., Batts, K. P., Therneau, T. M., Jorgensen, R. A., Dickson, R. E., & Lindor, K. D. (1999) · Hepatology · doi:10.1002/hep.510290301 · Cited by 234 · see citing works
Angulo, P., Lindor, K. D., Therneau, T. M., Jorgensen, R. A., Malinchoc, M., Kamath, P. S., & Dickson, E. R. (1999) · Liver International · doi:10.1111/j.1478-3231.1999.tb00020.x · Cited by 203 · see citing works
Angulo, P., Jorgensen, R. A., Keach, J. C., Dickson, R. E., Smith, C., & Lindor, K. D. (2000) · Hepatology · doi:10.1002/hep.510310209 · Cited by 179 · see citing works
Angulo, P., Dickson, E. R., Therneau, T. M., Jorgensen, R. A., Smith, C., DeSotel, C. K., Lange, S. M., Anderson, M. L., Mahoney, D. W., & Lindor, K. D. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80136-6 · Cited by 134 · see citing works
Natural history of primary biliary cirrhosis
Parés, A., & Rodés, J. (2003) · Clinics in Liver Disease · doi:10.1016/s1089-3261(03)00100-4 · Cited by 89 · see citing works
Corpechot, C., Poujol‐Robert, A., Wendum, D., Galotte, M., Chrétien, Y., Poupon, R. E., & Poupon, R. (2004) · Liver International · doi:10.1111/j.1478-3231.2004.0918.x · Cited by 48 · see citing works
Angulo, P., Jorgensen, R. A., & Lindor, K. D. (2001) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.05270.x · Cited by 39 · see citing works
- Authors
- Kilmurry, M. R., Heathcote, E. J., Cauch-Dudek, K., O’Rourke, K., Bailey, R. J., Blendis, L. M., Ghent, C. N., Minuk, G. Y., Pappas, S. C., Scully, L. J., Steinbrecher, U. P., Sutherland, L. R., Williams, C. N., & Worobetz, L. J.
- Affiliations
- University of Toronto (CA)
- Venue
- Hepatology
- Published
- 1996-05
- Volume
- 23
- Issue
- 5
- Pages
- 1148-1153
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2096061233
- Cited by
- 94
- References
- 2
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 2 · 2022: 1 · 2021: 1 · 2020: 1 · 2019: 2 · 2018: 5 · 2017: 1 · 2016: 1 · 2015: 1 · 2014: 5 · 2012: 2
- FWCI
- 4.72
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Medical Research Council Canada
- Medical Research Council
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Keywords
- primary biliary cirrhosis, ursodeoxycholic acid, Mayo risk score, serum bilirubin, prognostic factors, survival prediction, long-term survival
- MeSH terms
- Adult, Aged, Bilirubin, Canada, Follow-Up Studies, Humans, Liver Cirrhosis, Biliary, Middle Aged, Models, Theoretical, Predictive Value of Tests, Prognosis, Risk Factors, Ursodeoxycholic Acid, Survival Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
